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Objectives. The aim of this study was to determine whether the
release of nitric oxide (NO) from the ischemic heart increases
during exercise in patients with effort angina.
Background. Myocardial ischemia increases NO production in
the canine heart, but no such increase has been demonstrated in
the ischemic human heart.
Methods. Fifteen patients with effort angina underwent supine
ergometer exercise tests. All patients had severe proximal stenosis
(>90%) in the left anterior descending coronary artery. The
control group consisted of 17 subjects without coronary artery
disease or systemic hemodynamic abnormalities.
Results. Neither the lactate extraction ratio (LER) nor the
difference in NO concentration between coronary venous and
arterial blood (DVA[NO]) was affected by exercise in the control
subjects. In patients with effort angina, neither variable differed
from that in the control group at rest; however, exercise markedly
decreased LER and significantly increased DVA(NO) (from 4.7 6
0.3 to 16.5 6 1.6 mmol/liter, p < 0.001) in the patient group. The
extent of decrease in LER was significantly correlated with the
extent of increase in DVA(NO) in the patients with effort angina
(r2 5 20.837, p < 0.001).
Conclusions. Provocation of myocardial ischemia by exercise
stress increases NO production in the hearts of patients with
effort angina.
(J Am Coll Cardiol 1998;32:63–8)
©1998 by the American College of Cardiology
Recent studies in animals and humans have demonstrated that
the vascular endothelium plays an important role in the
regulation of regional blood flow by releasing endothelium-
derived relaxing factor (1–8), a major component of which is
nitric oxide (NO). NO is produced in the endothelium (9–14)
and other tissues of the heart, where it acts as a paracrine and
autocrine autacoid. In human hearts with restricted coronary
circulation, increases in myocardial oxygen demand relative to
oxygen supply cause angina pectoris and the release of lactate
into the coronary venous blood. In this condition, endogenous
vasodilators such as NO may be released to increase oxygen
supply (15–17). NO is present at low basal concentrations in
the well oxygenated myocardium, but its abundance increases
during ischemia, which may contribute to the improvement of
myocardial metabolic dysfunction (18,19). Although we de-
tected NO in coronary venous blood after transient ischemia in
dogs (20), a similar increase in NO has not been demonstrated
during provocation of myocardial ischemia in humans. During
metabolic stimulation of the human heart, released NO con-
tributes to coronary vasodilation (4,6). This contribution of
NO is reduced in patients exposed to risk factors for coronary
atherosclerosis, with a consequent reduction in vasodilation
during stress (21–23). Little is known of the in vivo metabolism
of NO during myocardial ischemia in humans. Therefore, we
have investigated whether NO is released during an angina
attack induced by an exercise stress test in patients with
coronary artery disease (CAD).
Methods
All study protocols were approved by the local Human
Investigations Committee, and study subjects gave written
informed consent. The study was performed while subjects
were in the supine position in a quiet room maintained at a
constant temperature of 22 to 24°C.
Study subjects. The experimental group comprised 15 pa-
tients (7 men and 8 women) who had CAD and a history of
stable exertional angina pectoris. Patients were selected during
admission to Osaka University Hospital from May 1994 to
August 1996, according to the following inclusion criteria: 1) a
history of stable effort-related angina pectoris; 2) coronary
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angiographic evidence of .90% stenosis (diameter reduction)
of the proximal left anterior descending coronary artery
(LAD); 3) absence of .50% stenosis of the left main, left
circumflex or right coronary artery; 4) presence of conditions
facilitating catheterization of the great cardiac vein; 5) pres-
ence of sinus rhythm; and 6) a normal contraction pattern in
the anterior and septal left ventricular wall and a normal
ejection fraction as assessed by biplane cineangiography. Left
ventricular end-systolic pressure was within normal limits
(,12 mm Hg). No patient showed either ST segment elevation
during an upright bicycle exercise test before catheterization
and while receiving their usual medical regimen or angio-
graphic or echocardiographic evidence of left ventricular hy-
pertrophy. Patients with valvular heart disease, a history of
angina at rest, clinical evidence of a previous myocardial
infarction, hyperlipidemia, hypertension, chronic heart failure,
renal dysfunction or diabetes mellitus were excluded. None of
the patients showed vasospasm of the epicardial coronary
arteries in response to either ergonovine or acetylcholine. The
control group comprised 17 subjects (9 men and 8 women) who
did not exhibit either CAD or systemic hemodynamic abnor-
malities.
Cardiac catheterization. Subjects underwent right and left
heart catheterization in the fasting state. After completion of
diagnostic coronary arteriography, either a 7F or 8F coronary
sinus flow catheter (Wilton-Webster) was advanced under
fluoroscopic guidance into the great cardiac vein through the
femoral vein (24). The catheter tip was positioned at the
junction of the anterior interventricular and great cardiac
veins. Coronary venous drainage at this site is thought to
originate mainly from the myocardium perfused through the
LAD (25). Aortic blood pressure was measured with a Judkins
catheter introduced through the right or left femoral artery.
Blood sampling. Either a 7F or 8F thermodilution coro-
nary blood flow catheter was positioned at the great cardiac
vein. Paired blood samples were obtained from the great
cardiac vein and descending aorta at rest and immediately
after the onset of symptom-limited submaximal cycling exer-
cise in the supine position and were placed in an ice bath
immediately after collection. After centrifugation of the blood
sample, the plasma was packed in dry ice for subsequent
determination of NO and lactate concentrations.
Measurement of NO and lactate levels. NO was measured
as described previously (26). Briefly, 1.5 ml of blood was
collected into heparinized tubes within 30 s and centrifuged for
5 min at 2,000g. The plasma fraction was diluted 1:1 with
nitrite-free and nitrate-free distilled water, and 400 ml of the
diluted sample was centrifuged at 2,000g in an ultrafree
microcentrifuge device to remove substances .10 kDa. The
filtrate was passed through a copper-plated cadmium column
to reduce nitrate to nitrite and then reacted with Griess
reagents. Absorbance at 540 nm was measured and represents
the total amount of plasma NO end products (nitrate plus
nitrite). The coronary arteriovenous difference in the concen-
tration of nitrate plus nitrite reflects the amount of NO
released from the myocardium. To measure the plasma lactate
level, blood (1 ml) was rapidly sampled and centrifuged, and
the lactate concentration in 0.2 ml of the plasma supernatant
was measured by enzyme assay (27). Lactate extraction ratio
(LER) was obtained by dividing the coronary arteriovenous
difference in lactate concentration by the arterial lactate
concentration and multiplying by 100%.
Exercise protocol. All antianginal medications were dis-
continued at least 24 h before the study. Patients and control
subjects underwent bicycle ergometer exercise tests in the
supine position. Each subject began to exercise at a work load
of 25 W, which was increased every 2 min in stepwise incre-
ments of 25 W. For all patients, the exercise was discontinued
when anginal pain occurred. Hemodynamic variables were
measured every minute. Blood was sampled simultaneously
from the great cardiac vein and descending aorta at rest and at
the end of exercise. A standard 12-lead electrocardiogram
(ECG) was recorded at rest and during exercise, and the data
were compared at the same exercise time and at equivalent
work loads.
Respiratory gas exchange variables. Gas exchange data
were collected throughout exercise with a breath-by-breath
respirometer system (Minato, model RM-200), which was
calibrated immediately before each study with a 2-liter calibra-
tion syringe and a gas mixture of 14.93% oxygen, 5.00% carbon
dioxide and 80.07% nitrogen. Oxygen uptake, carbon dioxide
output, minute ventilation and the respiratory gas exchange
ratio were obtained every 10 s during exercise.
Hemodynamic variables. Heart rate was measured by con-
tinuous ECG monitoring. Significant ST segment depression
on exercise testing was defined as .0.1 mV of horizontal or
downsloping ST segment depression measured 60 to 80 ms
after the J point and present on at least one lead.
Statistical analysis. Data are expressed as the mean
value 6 SEM. The analyses were performed using the SAS
system. The normality of the distribution and homogeneity of
variance had been assessed by using the Shapiro-Wilks test and
the F test, respectively. Comparison of descriptive character-
istics and performance and hemodynamic variables between
control subjects and patients was done using the unpaired t
test, the Welch t test or the Mann-Whitney U test, as appro-
priate. Comparison of NO in the great cardiac vein and aortic
root, the difference in NO concentration between coronary
venous and arterial blood (DVA[NO]) and LER before and
after exercise was done using the paired t test. Comparison of
NO in the great cardiac vein and aortic root, DVA(NO) and
Abbreviations and Acronyms
CAD 5 coronary artery disease
ECG 5 electrocardiogram, electrocardiographic
LAD 5 left anterior descending coronary artery
LER 5 lactate extraction ratio
NO 5 nitric oxide
DVA(NO) 5 difference in nitric oxide concentration between
coronary venous and arterial blood
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LER after exercise between the control group and patient
group was done using the Welch t test. Linear regression
analysis was used to correlate the changes in LER and those in
DVA(NO). A p value ,0.05 was considered statistically signif-
icant.
Results
The clinical characteristics of the patients with effort angina
and the control subjects are shown in Table 1. There were no
significant differences between the two groups with regard to
age, gender, body mass index, serum cholesterol, serum trig-
lycerides or ejection fraction. Performance and hemodynamic
variables at peak exercise for patients and control subjects are
shown in Table 2. The work load at maximal exercise and
exercise duration were significantly greater for the control
subjects than for the patients. All patients experienced chest
pain during exercise and developed ST-T segment changes of
the ischemic type on the one-lead ECG (0.21 6 0.03 mV).
Neither LER nor DVA(NO) was affected by exercise in the
control group. In patients at rest these variables were similar to
those of the control subjects. However, LER decreased signif-
icantly and DVA(NO) increased significantly in patients during
exercise (Table 3 and Fig. 1). Although we did not obtain the
total NO release because we did not measure coronary blood
flow, total cardiac release was also increased in patients during
exercise as compared with control subjects, when we estimated
coronary blood flow using the rate–pressure product (28). The
extent of the decrease in LER correlated significantly with the
extent of the increase in DVA(NO) (Fig. 2).
Discussion
The endogenous nitrovasodilator NO is continuously syn-
thesized from L-arginine by the action of NO synthase and
released mainly from endothelial cells. NO release is stimu-
lated by various local and circulating factors as well as by shear
stress of the bloodstream acting on the endothelial lining
(29,30). In the present study, exercise increased the NO
concentration in systemic arterial blood in both patients and
control subjects, suggesting that shear stress during exercise
enhances the production of NO in normal subjects (31).
Myocardial ischemia and cardiac NO levels. We have
previously shown that the concentration of NO end products in
plasma increases during acute focal myocardial ischemia and
reperfusion in dogs, and that this increase is proportional to
the extent of ischemia (20). We have shown that induction of
myocardial ischemia by exercise stress results in an increases in
NO production in the hearts of patients with effort angina.
Myocardial ischemia by itself has been shown to increase NO
Table 1. Clinical Characteristics of Control Subjects and Patients
With Effort Angina
Characteristic Control (n 5 17) Patients (n 5 15)
Gender (M/F) 9/8 7/8
Age (years) 60 6 4 61 6 3
Range 45–72 47–76
Obesity 2 3
Body mass index (kg/m2) 24 6 2 26 6 2
Serum cholesterol (mg/dl) 176 6 6 191 6 7
Serum triglycerides (mg/dl) 132 6 18 139 6 14
Ejection fraction (%) 72 6 5 69 6 4
Medication used previously
Beta-blockers 0 2
Long-acting nitrates 0 0
Calcium channel blockers 0 3
Aspirin 0 0
ACE inhibitors 0 0
Data presented are mean value 6 SEM or a number of subjects. ACE 5
angiotensin-converting enzyme; F 5 female; M 5 male.
Table 2. Performance and Hemodynamic Variables at Baseline and
Maximal Exercise for Patients and Control Subjects
Variable Control Subjects Patients
Work load (W) 117 6 11 83 6 4*
Percent predicted work capacity 87 6 3 65 6 4
Heart rate (beats/min)
Baseline 67 6 5 71 6 4
Maximal exercise 138 6 12 128 6 7
Blood pressure (mm Hg)
Systolic
Baseline 122 6 18 126 6 14
Maximal exercise 188 6 12 169 6 6
Diastolic
Baseline 70 6 5 72 6 6
Maximal exercise 102 6 5 94 6 3
RPP (102 mm Hg/min)
Baseline 82 6 4 89 6 6
Maximal exercise 259 6 15 216 6 12
Exercise duration (min) 7.1 6 1.8 5.3 6 1.2*
Peak V˙O2 (ml/min per kg) 22.4 6 2.1 20.1 6 1.9
Respiratory gas exchange ratio 1.1 6 0.06 1.0 6 0.04
*p , 0.05 compared with control subjects (analysis of variance). Data
presented are mean value 6 SEM. RPP 5 rate–pressure product; V˙O2 5 oxygen
consumption.
Table 3. Effects of Exercise on Plasma Nitric Oxide (nitrate plus










Great cardiac vein 25.0 6 1.3 43.5 6 1.8* 27.2 6 1.9 53.9 6 2.5*
Aortic root 21.1 6 1.8 39.1 6 1.2* 22.5 6 1.2 37.4 6 2.1*
DVA(NO) 3.9 6 0.2 4.4 6 0.3 4.7 6 0.3 16.5 6 1.6†‡
LER (%) 24.2 6 1.2 20.1 6 1.1 21.0 6 1.7 24.4 6 3.0*‡
*p , 0.05 and †p , 0.001 versus corresponding baseline value. ‡p , 0.01
versus corresponding control value. Data presented are mean value 6 SEM.
LER 5 lactate extraction ratio; NO 5 nitric oxide; DVA(NO) 5 coronary
arteriovenous difference in NO.
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production (18,20), although reperfusion after sustained isch-
emia is reported to impair basal NO synthesis (32). Because
NO and lactate production were correlated in the present
study, it is likely that the increase in NO synthesis during the
exercise stress test is attributable to myocardial ischemia. Both
cardiomyocytes (33) and endothelial cells (34) are thought to
be potential sources of NO in the ischemic heart; it is not
known which cell type was the major site of NO production in
the present study.
We did not measure coronary blood flow during exercise.
Because this variable may be reduced in patients with effort
angina, the NO concentration may appear to be increased
without any change in total production. Previous investigations
have demonstrated that the extent of increase in coronary
blood flow at rest and with mild exercise is identical in normal
subjects and patients with CAD (35–37). However, it is re-
ported that there were differences in coronary blood flow after
heavy exercise between the control and angina groups (28,38).
In the study of Holmberg et al. (38), because the maximal
coronary flow after supine heavy exercise was 370% of rest
coronary flow in the control group and 306% of rest coronary
flow in the angina group, the difference in coronary flow during
even heavy exercise could not account for the 240% increase in
coronary arteriovenous difference in NO after exercise in
patients with effort angina observed in the present study.
Possible sites of NO production. A decrease in NO-
dependent vasodilator responses in the microcirculation has
been observed in patients with atherosclerosis (39). Zeiher et
al. (40) showed that impaired endothelium-dependent vasodi-
lation of the coronary microcirculation is associated with
exercise-induced myocardial ischemia. Furthermore, athero-
sclerosis of epicardial conductance vessels impairs the activity
of endothelium-derived NO (22,23). Release of NO from
endothelial cells in response to shear stress or acetylcholine is
attenuated and induces vasoconstriction in such patients
(22,23). Even when the protein level of NO synthase is
decreased, decreases in pH or increases in intracellular Ca21
concentration during myocardial ischemia trigger the produc-
tion of NO through the activation of NO synthase. Because
cardiomyocyte may also produce NO during hypoxia (33), the
total amount of NO release during ischemia may increase by
release from cardiomyocytes and surrounding intact endothe-
lial cells of the ischemic zone.
Role of NO in coronary circulation. The contribution of
NO to dilation of coronary resistance vessels is controversial.
Inhibition of NO synthesis decreased the diameter of the
epicardial coronary artery without affecting coronary blood
flow or coronary vascular resistance in anesthetized dogs (41),
Figure 2. Correlation between the exercise-induced increase in
DVA(NO) and the decrease in LER.
Figure 1. Effects of exercise on the coronary arterio-
venous difference in NO (DVA[NO]) in the control
(A) and patient (B) groups.
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whereas inhibition of NO synthesis decreased the diameter of
the basal distal LAD and decreased basal coronary blood flow
in humans (6). Experimental studies revealed that administra-
tion of the NO synthase inhibitor reduced coronary blood flow
during coronary hypoperfusion (1,20). Although we have
shown that the human heart produces NO in response to
ischemic stress, it remains unclear whether increased NO
synthesis plays an important role in the regulation of the
coronary circulation during myocardial ischemia in patients
with CAD.
Possible mechanisms of increases in NO production. We
did not investigate the mechanism of NO release during
ischemia in the present study. We have previously shown that
cellular acidosis (42) or alpha1-adrenoceptor activation (43)
during ischemia contributes to NO-induced coronary vasodi-
lation in the canine myocardium. Exercise reduced the pH and
LER as well as increased the concentration of noradrenaline in
the coronary sinus of patients with effort angina (data not
shown). These chemical and humoral factors may contribute to
the release of NO.
Limitation of the present study. It has been suggested that
the position of the catheter used to sample blood from the
great cardiac vein may change during the course of an exper-
iment, thereby introducing variability into repeated blood
sampling (44). However, Magorien et al. (45) demonstrated a
highly significant correlation between these two measurements
during exercise. We confirmed that the position of the catheter
did not change when blood was sampled.
We thank Kayoko Yoshida and Yukiyo Nomura for their technical assistance
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